INTRODUCTION
Noninvasive mechanical ventilation (NIV), the mode of ventilation providing ventilator assistance by a mask without an invasive airway, is a major part of home mechanical ventilation (HMV), and an established treatment for chronic respiratory failure (CRF) (1) (2) (3) (4) (5) . Restrictive thoracic disorders (RTD) (including thoracic cage deformities and neuromuscular disorders (NMD)), obesity hypoventilation syndrome (OHS) and stable chronic obstructive pulmonary disease (COPD) with severe hypercapnia and nocturnal desaturation can be listed as the appropriate indications for domiciliary NIV use. NIV has been shown to decrease somnolence, fatigue and dyspnea with improved quality of life and survival in selected patients with these disorders (especially for amyotrophic lateral sclerosis (ALS), RTD, OHS) 6; whereas its role in stable COPD still remains controversial (6) (7) (8) .
Surveys from Europe, Australia, Hong Kong and United States provide some data about HMV use around the world (6) (7) (8) (9) (10) (11) (12) (13) . The 'Eurovent' study, representing up to 21526 HMV users (13% of whom tracheostomized) in 16 European countries, reported an estimated prevalence of HMV use as 6.6/100.000 people (9) . Marked variation was noted between countries in the prevalence and pattern of HMV prescription. A recent study from Australia and New Zealand, showed a minimum prevalence of HMV use 9.9 and 12/100.000, respectively (10) . The increased utilization was similarly observed in other studies from Hong Kong and Sweden (11, 12) . The most common indications were OHS and NMD, with variations in prescription patterns among participating centers based on center size, location and experience (10) . Another reason for this variation was thought to be uneven distribution of highly skilled enthusiasm with special competence and interest in HMV between hospitals (14) .
Previous small retrospective studies from Istanbul (23 pediatric NIV users) and Ankara (70 adult NIV users) reported limited regional data about domiciliary NIV use in Turkey however there is no national database or comprehensive data about prescription patterns. Although surveys from Europe, Australia and U.S. highlight their experience, surveys from developing countries such as Turkey are missing (15, 16) . The aim of this study is to define the approach of pulmonologists in Turkey for NIV use at home for CRF.
PATIENTS and METHODS
After reviewing the previously published surveys about NIV and blending with personal experiences and perceived areas of interest, the authors (AOU and ZK) drafted the questionnaire. The final version of the 38-question, self-administered survey was established after pilot testing done in 10 physicians and all of the authors, based on the feedbacks. The study protocol was approved by the Ethics Committee at Baskent University Faculty of Medicine.
The survey included mainly 3 sections as follows: 
RESULTS

Characteristics of Pulmonologists Using NIV for CRF
Out of 2205 pulmonologists receiving the survey, 27.1% (n= 596) responded. NIV was reported to be prescribed for home use by 340 physicians [57.1% of all responders and 81.0% of pulmonologists practicing NIV at clinical practice (n= 420)].
Among all responders, "home NIV prescribers" (i.e. NIV prescribers for CRF) (n= 340) had an approximately close distribution in terms of title and were mainly from teaching hospitals, whereas nonprescribers (n= 256) were mainly specialists and from non-teaching hospitals ( Table 1 ). The prescribers were younger with shorter duration of work in the pulmonary field, but more experienced for NIV use and ICU care. The median number of patients with ARF treated at hospital by NIV was 4 (IQR 2-7) for 'home NIV prescribers', as it was 2 (2-5) for nonprescribers (p= 0.001). fi rst and last group. Categorical variables were shown as n (%), whereas continuous variables as median (interquartile range).
All of the home NIV prescribers were also practicing NIV at clinical practice for ARF. Pulmonologists using NIV for ARF, but not for CRF were mainly specialists and from teaching hospitals ( Table 1) . They were working in the pulmonary field longer than home NIV prescribers, however the duration of experience in NIV use and ICU care was similar.
Indications of Domiciliary NIV Use
Chronic obstructive pulmonary disorder was the main indication for NIV use in CRF, as almost the entire home NIV prescribers (96.2%) were prescribing it for COPD. Restrictive thoracic disorders (74.4% of prescribers) and OHS (73.2%) were similarly preferred by the physicians, as followed by overlap syndrome (64.4%) and other disorders (7.4%). The estimated distribution of etiology for the prescriptions was as shown in Table 2 .
Ventilator Settings and Interface
Bi-level positive airway pressure ventilators with spontaneous and spontaneous/timed modes (BİPAP/S and BİPAP/ST), were the most preferred ventilators by 66.5 and 84.4% of the prescribers, respectively. Fewer physicians were claiming that they prescribe continuous positive airway pressure (CPAP) (37.1% of prescribers), average volume assured pressure support (AVAPS) (20.9%) and adaptive servoventilation (7.1%) for management of CRF. In terms of interface, most of the physicians were recommending oronasal mask (95.3% of prescribers), followed by nasal (60%), total face (11.5%) and helmet (0.3%) masks. The estimated distribution of ventilator and interface types among the prescriptions was as shown in Table 2 .
Most of the home NIV prescribers stated that they determined ventilator pressure settings based on arterial blood gas results (79.2% of prescribers), while some decided according to the results of sleep studies (22.9%) or amount of tidal volume/number of apnea detected on the ventilator during titration at the hospital (21.8%). Only 3.8% of the physicians mentioned that they were prescribing NIV for CFR without any titration. Nearly two thirds of the prescribers were providing education to the patient and/or caretakers about use and hygiene of ventilator and the accessories (i.e. interface and tubings) (65.9%), as more than a quarter (27.6%) was not providing any.
Humidifier Use
Humidifiers were stated to be prescribed by only half of the home NIV prescribers (50.9%). The main reason for not prescribing the humidifier for NIV use during CRF was claimed as being un-refundable by social security foundations (59.2% of physicians prescribing NIV without humidifier). The other causes were 'not considering it necessary' (27.6%) and 'not thinking that patient could use that in appropriate conditions' (34.8%).
DISCUSSION
The present study showed that domiciliary NIV was estimated to be prescribed by nearly two thirds of responders of our national survey done among pulmonologists all over Turkey. There was a variation in home-NIV prescription behavior associated with Table 2 . Estimated distribution of the prescriptions physicians" and hospitals" characteristics. The most common indication was mentioned as COPD. BİPAP/S and oronasal mask were reported to be the most commonly used mode and interface, respectively; whereas humidifier was reported to be prescribed by only half of the "home NIV prescribers", mainly due to reimbursement policies.
% of prescriptions
Indication for NIV
Home mechanical ventilation is an effective and growing long-term treatment for individuals with CRF secondary to a number of heterogeneous conditions. Rapid expansion of use in the last three decades could probably be due to higher number of physicians and medical staff experienced and skilled in NIV field with increased awareness of domiciliary NIV use, increasing numbers of patients surviving critical illness with appropriate indications for HMV and the ongoing technologic advances in NIV ventilators and equipments.
The overall response rate for our survey was quite low (27%), however it was a challenge to identify pulmonologists and ask them to complete the questionnaire. Although only HMV centers (defined as any hospital or outpatient unit initiating, prescribing or coordinating HMV use) were selected to be surveyed in Eurovent study, the largest trial about HMV performed in 16 European countries, the response rate was 62%9. Therefore our low response rate can be due to reluctance or low/no interest of some of the pulmonary physicians in NIV use CRF.
A substantial variation between countries in the prevalence and pattern of HMV prescription was revealed by Eurovent study, but the provision of HMV can also vary within each country (9, 14) . Half of the HMV prescribers were from non-universities; however universities (40% of prescribers) were reported to have more users, with longstanding HMV service serving as referral centers. A recent study from Australia and New Zealand also showed that prescribing centers were mainly tertiary (78%) hospitals. Likewise, we found that "home NIV prescribers" were mainly from teaching hospitals. Although skills and experience of the medical staff as well as the teaching status of the hospital can be associated with this variation in the prescriber profile; it can also be due to differences in individual attitudes, such as younger physicians with higher enthusiasm and special interest in domiciliary NIV use as found in our study. One fifth of the physicians applying NIV for ARF during their clinical practice were not prescribing NIV for home use. The proportion of non-teaching hospitals and specialists were higher among these physicians compared to home NIV prescribers. We can only speculate that those physicians had no or lower interest and/or available resources to follow-up patients with CRF on HMV.
In our study, COPD was estimated as the main indication of domiciliary NIV, as almost all of the prescribers were prescribing NIV for this indication. COPD was nearly three fourths of all the home NIV prescriptions. This is in concordance with data from Eurovent and Hong Kong studies, with higher rates of COPD prescriptions (34-49%) (9, 12) . However COPD was reported as an uncommon indication (8%) by Garner et al. This difference could be due to higher rates of smoking and easier access to NIV for COPD in Turkey compared to Australia and New Zealand (10) . It may also be due to our survey population, consisting of only pulmonologists. Obesity hypoventilation syndrome, commonest indication (31%) reported by Garner et al, was estimated to be the indication for one tenth of the prescriptions in Turkey as much as overlap syndrome (10) . Although home NIV was claimed to be prescribed for RTD by nearly 75% of the physicians, it was guessed as an indication only 5% of home NIV prescriptions. This might also be due to surveying only pulmonologists; since anesthesiologists in Turkey might prescribe more for RTD after an acute onset of respiratory failure treated in intensive care unit.
Although a significant proportion of our caregivers declared that they preferred bi-level modes, few of them reported CPAP prescription for COPD patients. It must be emphasized that CPAP is not a ventilatory mode and should better not be routinely used to treat hypoventilation; however, it can be prescribed for only a subset of patients with OHS or sleep related disorders (3). Additionally, BİPAP with back-up rate (BİPAP/ST), recommended usually in patients with ALS or Duchenne muscular dystrophy and reimbursed in Turkey in case of high inspiratory positive airway pressure levels or in presence apneas observed during stay in intensive care unit, was claimed to be nearly 30% (reaching up to 85% for some physicians) of NIV prescriptions. Since appropriate indications were not reported in accordance with this rate, either BİPAP/ST is over-prescribed for inappropriate conditions or the rate for related conditions was under-estimated (3, 18) . In either case, continuing education may help the physicians to improve the knowledge and skill on appropriate domiciliary NIV application.
Domiciliary NIV was reported to be implemented by utilizing mainly arterial blood gas analyses (96%), followed by polysomnography (77%) and transcutaneous CO 2 monitoring (62%) (10) . Our results, as most determine settings based on arterial blood gas results, are compatible with these findings. However, it should be noted that few physicians reported prescribing it without any form of titration, which is very improper.
Dry gas inhalation during NIV application can provoke some detrimental effects on airway mucosa (19) . Currently, active humidification is suggested for NIV by American Association of Respiratory Care (20) . In accordance with that, humidifier use was reported as 87% by Garner et al. Unfortunately, in our study, nearly half of the caregivers reported not prescribing humidifier with NIV, mainly due to reimbursement issues (10) . Its use in symptomatic patients (such as nasal congestion or thick or tenacious secretions) with risk factors (mouth air leaks, high FiO 2 , high IPAP) may be helpful to prevent deleterious effects of NIV and improve compliance and adherence. Therefore, health policies regarding to this issue might better be changed in favor of refunding humidifier in selected group of patients with CRF using NIV.
Limitations of this study were summarized in our prior report (17) . A survey by e-mail requesting detailed information on practices is never completely accurate (recall bias) and there might be a selection bias, favoring NIV prescribing physicians to respond. Our response rate of 27% can be due to including only pulmonologists.
In conclusion, this study showed that there is wide variation in Turkey for domiciliary NIV prescription pattern. The causal differences of this variation are still mysterious; however differences in individual attitudes for domiciliary NIV application can be a possible explanation. COPD was claimed to be the most common indication, and bi-level ventilators with oronasal mask were reported to be the most commonly prescribed equipments. With an expanding list of medical indications, resulting in HMV population to become more and more heterogeneous; national data registries and further research providing prevalence of domiciliary NIV use and its outcomes are needed. Continuing education and increased availability of resources with development of home care companies and evidencebased clinical practice standards (including refundable humidification) on NIV use for CRF are required to ensure best practice policies for this group of patients.
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